Refeyn

Leading CROs and CDMOs Turn to Mass Photometry for Rapid Protein, mRNA and Viral Vector Analytics

As CROs and CDMOs expand their role in biopharma development and manufacturing, fast, accurate bioanalytic technologies remain critical to biotherapeutic affordability.

News

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

German CDMO Rentschler Biopharma is collaborating with the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organization specializing in the advancement of cell and gene therapies, and Oxford-based mass photometry specialist Refeyn, to improve the manufacturing adeno-associated viruses (AAVs).

Top-Feature

BIO Deutschland e.V.

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Rentschler Biopharma SE

Refeyn Ltd.

Refeyn

Leading CROs and CDMOs Turn to Mass Photometry for Rapid Protein, mRNA and Viral Vector Analytics

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

Top-Feature

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Upcoming Virtual Events

Siemens Joins the Global Impact Coalition

Virtual Event

Digitalization in the Chemical Industry

Refeyn

Leading CROs and CDMOs Turn to Mass Photometry for Rapid Protein, mRNA and Viral Vector Analytics

Rentschler in Collaboration to Improve AAV-Manufacturing for Gene Therapies

Top-Feature

German Biotech Days 2026: Biotechnology as The Key to Industrial Competitiveness

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Upcoming Virtual Events

Siemens Joins the Global Impact Coalition

Virtual Event

Digitalization in the Chemical Industry

Newsletter & e-edition